Resistance

As with all other anti-HIV drugs, strains of HIV that are resistant to fosamprenavir (Telzir) may emerge after a period of treatment. The emergence of drug-resistant strains coincides with a fall in the effectiveness of the drug.

As fosamprenavir is a pro-drug of amprenavir (Agenerase), it is susceptible to the same mutations as amprenavir, although clinical studies have found that ritonavir boosting lowers the rate of resistance emergence.

The main mutation associated with amprenavir resistance is I50V. There is evidence to suggest that this mutation is unique to amprenavir and fosamprenavir. Consequently, people with resistance to other protease inhibitors may benefit from the use of fosamprenavir, although I50V may reduce the response to lopinavir. Other mutations associated with fosamprenavir resistance include:1

  • V32I.
  • M46I/L, which reduces sensitivity to all protease inhibitors except for saquinavir (Invirase).2
  • I47V.3
  • I54L/M.
  • I84V, which confers resistance to all available protease inhibitors.
  • L90M, which causes resistance to saquinavir and nelfinavir (Viracept).

References

  1. Elston R et al. Lack of resistance to boosted 908 confirmed through 48 weeks of therapy in naïve subjects. Antivir Ther 8: S334, 2003
  2. Prado JG et al. Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity. AIDS 16: 1009-1017, 2002
  3. Schurmann D et al. Evolution of resistance during first-line treatment with boosted fosamprenavir is associated with baseline mutations. AIDS 20: 138-140, 2006
This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.